Biogen Idec

NASDAQ: BIIB
$275.84
-$4.45 (-1.6%)
Closing price January 15, 2021
Tuesday's midday analyst calls included Peloton Interactive, Biogen, Square and Lockheed Martin.
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
These four top stocks offer investors with a longer time horizon solid value and outstanding entry points. They are outstanding ideas for those looking to leave pricier growth companies but wanting...
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Tuesday's top analyst upgrades and downgrades included AbbVie, Beyond Meat, Biogen, Eli Lilly, Levi Strauss, Nvidia, Pfizer, Plug Power, Raytheon, Square and Wayfair.
24/7 Wall St. has tracked multiple analyst calls regarding the expected approval or nonapproval of aducanumab as the first viable treatment against Alzheimer's disease.
Monday's top analyst upgrades and downgrades included Albermarle, Biogen, Fisker, General Motors, Livent, Marriott International, Uber Technologies and Yelp.
Thursday's top analyst upgrades and downgrades included Biogen, Honeywell, Microsoft, Ping Identity, Qualcomm, Verizon Communications and Wendy's.
Biogen shares rocketed up on Wednesday after briefing documents from the FDA provided evidence of the effectiveness of the firm’s Alzheimer’s disease treatment.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amazon.com, Amgen, Biogen, Hasbro, Kinder Morgan, SAP, Spotify and Twitter.
Biogen reported better than expected third-quarter financial results with disappointing guidance before the markets opened on Wednesday.
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.